O-serotype distribution of Escherichia coli bloodstream infection isolates in critically ill patients in The Netherlands

D M Verboom; M R J Varkila; B Morrow; T Davies; P Ibarra de Palacios; J Poolman; P W M Hermans; E G Dudley; E Roberts; O L Cremer; M J M Bonten

doi:10.1016/j.vaccine.2021.02.031

O-serotype distribution of Escherichia coli bloodstream infection isolates in critically ill patients in The Netherlands

Vaccine. 2021 Mar 19;39(12):1670-1674. doi: 10.1016/j.vaccine.2021.02.031. Epub 2021 Feb 25.

Authors

D M Verboom¹, M R J Varkila², B Morrow³, T Davies³, P Ibarra de Palacios⁴, J Poolman⁵, P W M Hermans⁶, E G Dudley⁷, E Roberts⁷, O L Cremer⁸, M J M Bonten⁹

Affiliations

¹ Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands; Department of Intensive Care, University Medical Center Utrecht, Utrecht, the Netherlands. Electronic address: [email protected].
² Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands; Department of Intensive Care, University Medical Center Utrecht, Utrecht, the Netherlands.
³ Janssen Research & Development, LLC, Raritan, NJ, USA.
⁴ Janssen Vaccines, Bern, Switzerland.
⁵ Janssen Vaccines & Prevention B.V., Leiden, Netherlands.
⁶ Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands; Janssen Vaccines & Prevention B.V., Leiden, Netherlands.
⁷ E. coli Reference Center, Department of Food Science, The Pennsylvania State University, University Park, PA, United States.
⁸ Department of Intensive Care, University Medical Center Utrecht, Utrecht, the Netherlands.
⁹ Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, the Netherlands.

PMID: 33642161
DOI: 10.1016/j.vaccine.2021.02.031

Abstract

Objectives: Invasive infections by extra-intestinal pathogenic Escherichia coli (ExPEC) strains are increasing. We determined O-serogroups of E. coli isolates from ICU patients having bloodstream infections (BSI) and the potential coverage of a 10-valent O-polysaccharide conjugate vaccine currently in development for the prevention of invasive ExPEC disease.

Methods: We studied E. coli BSI among patients admitted to a tertiary ICU in the Netherlands between April 2011 and November 2016. O-serogroups were determined in vitro by agglutination and whole genome sequencing.

Results: Among 714 ICU patients having BSI, 70 (10%) had an E. coli BSI. Among 68 (97%) isolates serogrouped, the most common serogroups were O25 (n = 11; 16%), O8 (n = 5; 7%), O2 (n = 4; 6%), O6 (n = 4; 6%), and O15 (n = 4; 6%). The theoretical coverage of a 10-valent ExPEC vaccine was 54% (n = 37).

Conclusions: A multi-valent ExPEC O-polysaccharide conjugate vaccine in development could potentially aid in the prevention of E. coli BSI in Dutch ICU patients.

Keywords: Bloodstream infections; Escherichia coli; ExPEC; ICU; Vaccine.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Critical Illness
Escherichia coli / genetics
Escherichia coli Infections* / epidemiology
Humans
Netherlands / epidemiology
Sepsis* / epidemiology
Serogroup